Use of Antileukotriene Drugs in Treatment of Children with Bronchial Asthma
PDF

Keywords

children
bronchial asthma
montelukast
basic therapy

Abstract

There were examined 65 children with partially controlled and uncontrolled bronchial asthma (BA) in the exacerbation phase at the age of 5-7 years. Acute respiratory viral infections were often complicated by wheezing (49.2%) and pneumonia (16.8%). Unfortunately, most of these episodes were treated using antibacterial therapy despite normal values of the complete blood count and no infiltrative changes in the chest radiography. Children of Group I underwent basic therapy of BA in the form of         inhaled corticosteroids (ICS), patients of Group II received antileukotriene drug – montelukast (Milukante) in addition to basic therapy of BA. When assessing the values of peakflowmetry a peak flow rate was found to be improved in all children (р<0.001), however, in children who additionally received montelukast better parameters of the average daily bronchial patency (ADBP) were observed 77.29±1.17% vs. 72.87±0.73% in Group І (р<0.05). There was a similar tendency when assessing the increase in the ADBP 19.9±1.1% and 23.35±1.18% in Group І and ІІ, respectively. After inpatient treatment, patients were prescribed monotherapy with ICS (Group I) or montelukast (Group II) for 3 months. In children who received montelukast parameters of the ADBP were found to be higher 81.29±1.17% vs. 89.27±1.11% in Group І (р<0.05) and, accordingly, the assessment of general well-being was higher, too. Such differences between groups are explained by the fact that patients preferred taking montelukast to taking ICS.
PDF

References

Shit SM, Revenko NYu. , Gorelko TG, et al. Antileukotriene drug in treatment of allergic diseases in children. Perinatologiya i pediatriya 2013;3(55):92-95.

Reheda MS, Reheda MM, Furdychko LO, et al. Bronchial asthma [monograph]. Lviv. 2012;147.

Zaitseva OV. Wheezing in paediatric practice. Role of inhaled bronchodilator therapy. Novyny medytsyny ta farmatsii 2008;19(261):43-47.

Korets HYu, Zaliska OM. Pharmacoeconomic aspects of treatment of bronchial asthma on the basis of evidence-based medicine. Provizor 2009;10:45-49.

Korostovtsev DS, Breykin DV. Peak expiration velocity in healthy children. Allergologiya 2006;2:39-42.

Khaitova RM, Ilyina NI, Latysheva TV, et al. Rational pharmacotherapy of allergic diseases. Khaitova RM, Ilyina NI, Latysheva TV,editors. Litterra. Moscow. 2007;502,

Tkach YeP, Khukhlina OS, Voievidka OS et al. Pharmaceutical care. Nova Knyha. Vinnytsia. 2014;519.

Becker LA, Hom J, Villasis-Keever M, et al. Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis. Cochrane Database Syst Rev. Internet 2015;3(9). Available from: http://www.ncbi.nlm.nih.gov/pubmed/26333656

Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report2015_Tracked.pdf

Hesselmar B, Enelund A-C, Eriksson B, et al. The heterogeneity of asthma phenotypes in children and young adults. J Allergy. 2012; Article ID 163089, 6-8.

Aganche I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy 2012;67(7):835-846. Available from: http://dx.doi.org/10.1111/j.1398-9995.2012.02832.x PubMed PMID: 22594878. doi: 10.1111/j.1398-9995.2012.02832.x.

Kocevar VS, Bisgaard H, Jönsson L, Valovirta E, Kristensen F, Yin DD, et al. Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries.. Chest 2004;125(5):1680-1684. Available from: http://www.diseaseinfosearch.org/result/633 PubMed PMID: 15136376.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Downloads

Download data is not yet available.